Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 699-706

  Ikeda, Sadakatsu ^a   Hansel, Donna E ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetic aberrations; Immune therapy; Targeted therapy; Urothelial carcinoma

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; AMP 224; ANTINEOPLASTIC AGENT; BAY 1163877; BEVACIZUMAB; BRIVANIB; CISPLATIN; DNA BINDING PROTEIN; DOXORUBICIN; DURVALUMAB; ERDAFITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; INFIGRATINIB; IPILIMUMAB; LAPATINIB; LENVATINIB; METHOTREXATE; MPDL 3280A; NINTEDANIB; NIVOLUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ARID1A PROTEIN, HUMAN; MLL2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UTX PROTEIN, HUMAN;

ARID1A GENE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; EP300 GENE; ERCC2 GENE; FGFR3 GENE; GENE; GENE MUTATION; HUMAN; KDM6A GENE; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; ONCOGENE NEU; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PROGRESSION FREE SURVIVAL; RB GENE; REVIEW; STAG2 GENE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; CARCINOMA, TRANSITIONAL CELL; DISEASE MANAGEMENT; EXPERIMENTAL THERAPY; GENETICS; IMMUNOTHERAPY; MUTATION; PATHOLOGY; PROCEDURES; TRENDS; UROLOGIC NEOPLASMS;

CARCINOMA, TRANSITIONAL CELL; DISEASE MANAGEMENT; DNA-BINDING PROTEINS; HISTONE DEMETHYLASES; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; THERAPIES, INVESTIGATIONAL; TRANSCRIPTION FACTORS; UROLOGIC NEOPLASMS;

EID: 84941023230     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.06.004     Document Type: Review

References (110)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. American Cancer Society. What is bladder cancer?. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-what-is-bladder-cancer.
3. Hinotsu S., Akaza H., Miki T., et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol 2009, 16:64-69.
4. Freedman N.D., Silverman D.T., Hollenbeck A.R., et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306:737-745.
5. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
6. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
7. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10:1066-1073.
8. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8:1050-1055.
9. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001, 19:2638-2646.
10. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006, 42:50-54.
11. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
12. Bellmunt J., von der Maase H., Mead G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012, 30:1107-1113.
13. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999, 354:533-540.
14. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003, 361:1927-1934.
15. Winquist E., Kirchner T.S., Segal R., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004, 171:561-569.
16. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. [discussion 205-206].
17. Rodel C., Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence?. J Clin Oncol 2014, 32:3787-3788.
18. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403-407.
19. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989, 64:2448-2458.
20. Hvd Maase., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
21. Camidge D.R., Pao W., Sequist L.V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014, 11:473-481.
22. Weisberg E., Manley P.W., Cowan-Jacob S.W., et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345-356.
23. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013, 31:3133-3140.
24. Guo G., Sun X., Chen C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45:1459-1463.
25. Comprehensive molecular characterization of urothelial bladder carcinoma Nature 2014, 507:315-322.
26. Ross J.S., Wang K., Al-Rohil R.N., et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014, 27:271-280.
27. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
28. Leijen S., Beijnen J.H., Schellens J.H. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010, 5:186-191.
29. NCI-MPACT: molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors. Clinicaltrials.gov. NCT01827384.
30. Said R., Hong D.S., Warneke C.L., et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013, 4:705-714.
31. Ng S.B., Bigham A.W., Buckingham K.J., et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010, 42:790-793.
32. Grembecka J., He S., Shi A., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012, 8:277-284.
33. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011, 11:481-492.
34. Samartzis E.P., Gutsche K., Dedes K.J., et al. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014, 5:5295-5303.
35. Chi P., Allis C.D., Wang G.G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469.
36. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
37. Milowsky M.I., Iyer G., Regazzi A.M., et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013, 112:462-470.
38. Phase II evaluating efficacy of temsirolimus in 2 line therapy for patients with advanced bladder cancer (VESTOR). Clinicaltrials.gov. NCT01827943.
39. Sirolimus, cisplatin, and gemcitabine hydrochloride in treating patients with bladder cancer. Clinicaltrials.gov. NCT01938573.
40. Neoadjuvant rapamycin in patients undergoing radical cystectomy. Clinicaltrials.gov. NCT01827618.
41. Buparlisib in metastatic transitional cell carcinoma of the urothelium. Clinicaltrials.gov. NCT01551030.
42. Phase I study of triciribine phosphate monohydrate (TCN-PM, VD-0002) in adult subjects with metastatic cancer. Clinicaltrials.gov. NCT00363454.
43. MK2206 and paclitaxel in treating patients with locally advanced or metastatic solid tumors or metastatic breast cancer. Clinicaltrials.gov. NCT01263145.
44. Wagle N., Grabiner B.C., Van Allen E.M., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4:546-553.
45. Gayther S.A., Batley S.J., Linger L., et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303.
46. Phase 2 study of mocetinostat in patients with urothelial carcinoma having inactivating alterations of specific genes. Clinicaltrials.gov. NCT02236195.
47. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414.
48. Study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy. Clinicaltrials.gov. NCT01301391.
49. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008, 8:714-724.
50. Ma Y., Kurtyka C.A., Boyapalle S., et al. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 2008, 68:6292-6299.
51. Compe E., Egly J.M. TFIIH: when transcription met DNA repair. Nat Rev Mol Cell Biol 2012, 13:343-354.
52. Van Allen E.M., Mouw K.W., Kim P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4:1140-1153.
53. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
54. Lecia V, Sequist PC, Andrea V, Josep T, Jan HMS, Jean-Pierre D, Patricia LoRuss7, Ross Camidge D, Manuel Hidalgo Medin9, Martin S, Mario C, Gary Tian G, Steven W, Jesus C. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Available at: [accessed on 13.05.15]. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404%26sKey=a56e6bb6-7ce7-4f58-89a7-f118d4efb710%26cKey=25b2209a-5959-45f1-a777-4414cb7cdf21%26mKey=6ffe1446-a164-476a-92e7-c26446874d93.
55. Rodrigo Dienstmann RB, Barbara A, Jordi R, Andrea V, Anas G, Suso P, Hans S, Timothy P, Bob Z, Kim S, Yusri E, Chris T, Vijay Peddareddigar4, Josep T, Feng Roger Lu4, Jean-Charles S. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Available at: [accessed on 13.05.15]. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404%26sKey=a56e6bb6-7ce7-4f58-89a7-f118d4efb710%26cKey=ad57afb0-3d24-44fc-8ee8-ae21e404d85a%26mKey=6ffe1446-a164-476a-92e7-c26446874d93.
56. Phase I dose escalation pan-FGFR (fibroblast growth factor receptor) inhibitor. Clinicaltrials.gov. NCT01976741.
57. Study of oral lucitanib (E-3810), a dual VEGFR-FGFR tyrosine kinase inhibitor, in patients with solid tumors. Clinicaltrials.gov. NCT01283945.
58. Gozgit J.M., Wong M.J., Moran L., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012, 11:690-699.
59. Okamoto I., Kaneda H., Satoh T., et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010, 9:2825-2833.
60. Jonker D.J., Rosen L.S., Sawyer M.B., et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 2011, 22:1413-1419.
61. Yamamoto Y., Matsui J., Matsushima T., et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014, 6:18.
62. Solomon D.A., Kim J.S., Bondaruk J., et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013, 45:1428-1430.
63. Arteaga C.L., Sliwkowski M.X., Osborne C.K., et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
64. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007, 25:2218-2224.
65. Daugaard G., Sengelov L., Agerbaek M., et al. Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. ASCO Meeting Abstracts 2013, 31:252.
66. Finlay C.A., Hinds P.W., Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989, 57:1083-1093.
67. Mitra A.P., Lin H., Datar R.H., Cote R.J. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 2006, 5:67-77.
68. Keegan P.E., Lunec J., Neal D.E. P53 and p53-regulated genes in bladder cancer. Br J Urol 1998, 82:710-720.
69. Baas I.O., Mulder J.W., Offerhaus G.J., et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994, 172:5-12.
70. Farhang Ghahremani M., Goossens S., Haigh J.J. The p53 family and VEGF regulation: "it's complicated". Cell Cycle 2013, 12:1331-1332.
71. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
72. Katso R., Okkenhaug K., Ahmadi K., et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675.
73. Currie R.A., Walker K.S., Gray A., et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999, 337(Pt 3):575-583.
74. Platt F.M., Hurst C.D., Taylor C.F., et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009, 15:6008-6017.
75. Wagle N., Grabiner B.C., Van Allen E.M., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4:546-553.
76. Ma C.X., Gao F., Naughton M., et al. A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC). ASCO Meeting Abstracts 2014, 32:553.
77. Andersen C.L., Asmar F., Klausen T., et al. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep 2012, 2:1-3.
78. Mitra A.P., Birkhahn M., Cote R.J. P53 and retinoblastoma pathways in bladder cancer. World J Urol 2007, 25:563-571.
79. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998, 90:1072-1079.
80. Horowitz J.M., Park S.H., Bogenmann E., et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990, 87:2775-2779.
81. Chatterjee S.J., George B., Goebell P.J., et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004, 203:762-770.
82. Polyak K., Garber J. Targeting the missing links for cancer therapy. Nat Med 2011, 17:283-284.
83. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
84. Murgue B., Tsunekawa S., Rosenberg I., et al. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 1994, 54:5206-5211.
85. Matthew I., Milowsky C.D., Ignacio D.M., Satinder J., Frederick E.M., Christopher S., et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol 2013, 31(Suppl. 6):2013. [abstr 255].
86. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
87. Nahta R. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012, 2012:428062.
88. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
89. Gao J., Aksoy B.A., Dogrusoz U., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1.
90. Network CGAR Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
91. Hansel D.E., Swain E., Dreicer R., Tubbs R.R. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008, 130:274-281.
92. Yan M., Parker B.A., Schwab R., Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014, 40:770-780.
93. Groenendijk F.H., de Jong J., Fransen van de Putte E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2015.
94. Efficacy of combination of trastuzumab to gemcitabine - platinum advanced or metastatic urothelial carcinoma (CVH-CT02). Clinicaltrials.gov. NCT01828736.
95. A double blind randomised study of lapatinib and placebo in metastatic TCC of the urothelium (LaMB). Clinicaltrials.gov. NCT00949455.
96. Carthon B.C., Wolchok J.D., Yuan J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010, 16:2861-2871.
97. First-line gemcitabine, cisplatin+ipilimumab for metastatic urothelial carcinoma. Clinicaltrials.gov. NCT01524991.
98. Powles T., Vogelzang N.J., Fine G.D., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2014, 32:5011.
99. A study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer. Clinicaltrials.gov. NCT02108652.
100. Lutzky J., Antonia S.J., Blake-Haskins A., et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 2014, 32:3001.
101. Segal N.H., Antonia S.J., Brahmer J.R., et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstracts 2014, 32:3002.
102. A study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045). Clinicaltrials.gov. NCT02256436.
103. A phase 1/2, open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. Clinicaltrials.gov. NCT01928394.
104. Study to assess the safety, tolerability, and pharmacokinetics of AMP-224 in patients with advanced cancer. Clinicaltrials.gov. NCT01352884.
105. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
106. Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013, 12:489-492.
107. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
108. Patel S.P., Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015, 14:847-856.
109. Nahta R., Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
110. Menis J., Hasan B., Besse B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev 2014, 23:367-378.